Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [7] Pomalidomide was approved for medical use in the United States in February 2013, [10] and in the European Union in August 2013. [8] It is available as a generic ...
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
Severe side effects include low blood platelets, low white blood cells, and blood clots. [8] The dose may need to be adjusted in people with kidney problems. [8] Lenalidomide is closely related to thalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus. [8]
Earlier this month, biotech powerhouse Celgene announced that the European Commission approved the combinational therapy of pomalidomide, known in the United States as Pomalyst, and dexamethasone ...
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene ...
Oral Anti-Cancer Therapy REVLIMID ® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Treatment indicated for patients with transfusion-dependent anaemia ...
A 2009 review noted, "Deep venous thrombosis and pulmonary embolism are the major side effects of thalidomide and lenalidomide. Lenalidomide causes more myelosuppression, and thalidomide causes more sedation. Chemotherapy-induced peripheral neuropathy and thrombocytopenia are major side effects of bortezomib."
Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as Treatment for Patients with Relapsed/Refractory Multiple Myeloma - a Rare Form of Blood Cancer BOUDRY, Switzerland ...